for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Peptidream Inc

4587.T

Latest Trade

4,140.00JPY

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

4,135.00

 - 

6,540.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
4,140.00
Open
--
Volume
--
3M AVG Volume
8.17
Today's High
--
Today's Low
--
52 Week High
6,540.00
52 Week Low
4,135.00
Shares Out (MIL)
129.82
Market Cap (MIL)
546,693.80
Forward P/E
95.05
Dividend (Yield %)
--

Next Event

Q3 2021 PeptiDream Inc Earnings Release

Latest Developments

More

Alnylam, PeptiDream Enter Into Collaboration Agreement

Biohaven Receives FDA May Proceed Letter To Begin Phase 2 Trial Of Intranasal Vazegepant To Treat Lung Inflammation After Covid-19 Infection

PeptiDream announces drug discovery and development agreement with Santen Pharmaceutical

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Peptidream Inc

PeptiDream Inc. is a Japan-based bio-venture company started by the University of Tokyo and principally engaged in the discovery and development of non-standard peptide therapeutics. The Company operates the Peptide Discovery Platform System (PDPS), a drug development platform system and conducts research and development (R&D) on new drug candidates based on the joint R&D with pharmaceutical companies in Japan and overseas. The Company is involved in the business centered on drug development based on special peptides. The Company's businesses include drug discovery joint R&D, PDPS technology loan (PDPS technology license) and expansion of its own pipeline through strategic alliance (strategic alliance or in-house drug discovery).

Industry

Biotechnology & Drugs

Contact Info

3-25-23, Tono-machi, Kawasaki-ku

KAWASAKI-SHI, KNG

210-0821

Japan

+81.44.2701300

https://www.peptidream.com/

Executive Leadership

Patrick Reid

President, Representative Director

Kiyofumi Kaneshiro

Vice President, Director

Keiichi Masuya

Vice President, President of Subsidiary, Director

Yukinori Hanafusa

Independent Director

Toshio Nagae

Independent Director

Key Stats

2.22 mean rating - 9 analysts
Sell
Hold
Buy
Price To Earnings (TTM)
105.31
Price To Sales (TTM)
42.90
Price To Book (MRQ)
24.65
Price To Cash Flow (TTM)
94.19
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
26.87
Return on Equity (TTM)
24.87

Latest News

Latest News

Japan's Fujitsu, Mizuho, PeptiDream to form joint venture to develop COVID-19 treatments

Fujitsu Ltd, Mizuho Financial Group Inc, and drugmaker PeptiDream Inc said on Thursday they are forming a joint venture to develop treatments for COVID-19.

Japan's PeptiDream to work with Merck in developing COVID-19 therapies

Japanese drug-discovery company PeptiDream Inc said on Friday it would collaborate with Merck & Co in developing COVID-19 therapies.

Biotech-for-hire PeptiDream charts new path and becomes short target

The promise of PeptiDream Inc's drug-discovery technology and its lucrative research-for-hire contracts have made it a darling of the Tokyo stock market. Now, those gains have made it a target for short-seller Muddy Waters.

FOCUS-Biotech-for-hire PeptiDream charts new path and becomes short target

The promise of PeptiDream Inc's drug-discovery technology and its lucrative research-for-hire contracts have made it a darling of the Tokyo stock market. Now, those gains have made it a target for short-seller Muddy Waters.

RPT-BRIEF-Shionogi & Co Ltd Announces Agreements On Collaborative Research With Peptidream For New Peptide Drug Conjugate(Pdc) Discovery

* SHIONOGI & CO LTD ANNOUNCES AGREEMENTS ON COLLABORATIVE RESEARCH WITH PEPTIDREAM INC FOR NEW PEPTIDE DRUG CONJUGATE (PDC) DISCOVERY Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up